Clinical significance of serum p53 antibodies in oral cancer

Tumori

Volumn 92, Issue 2, 2006, Pages 134-139

  Sainger, Rachana Narendra Singh ^a   Shah, Manisha Hasmukhray ^a   Desai, Amisha Anil ^a   Shukla, Shilin Nandubhai ^a   Shah, Pankaj Manubhai ^a   Telang, Shaila Dattatraya ^b   Patel, Prabhudas Shankerbhai ^a  

^a GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

^b M S UNIVERSITY OF BARODA   (India)

Author keywords

Oral cancer; Oral precancerous conditions; p53 antibodies; Prognosis; Treatment monitoring

Indexed keywords

CANCER ANTIBODY; P53 ANTIBODY; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; PROGNOSIS; SMOKING; AGED; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY; PRECANCER; PREDICTION AND FORECASTING; SURVIVAL;

ADULT; AGED; ANTIBODIES, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33744758908     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200209     Document Type: Article

References (21)

1. Hospital based Cancer Registry, The Gujarat Cancer & Research Institute, 2001.
2. Silverman S, Gorsky M, Lozada F: Oral leukoplakia and malignant transformation, a follow-up study of 257 patients. Cancer, 53: 563-568,1984.
3. Crawford LV, Pim DC, Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer, 30: 403-408, 1982.
4. Soussi T: p53 antibodies in the sera of patients with various types of cancers: A review. Cancer Res, 60: 1777-1788, 2000.
5. Ralhan R, Nath N, Agarwal S, Mathur M, Wasylyk B, Shukla N: Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Clin Cancer Res, 4: 2147-2152, 1998.
6. Tavassoli M, Brunel N, Maher R, Johnson NW, Soussi T: p53 antibodies in the saliva of patients with squamous cell carcinoma of the oral cavity. Int J Cancer, 78: 390-391, 1998.
7. Shimada H, Ochiai T, Nomura F, Japan p53 Antibody Research Group: Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer, 97: 682-689, 2003.
8. Sangrajrang S, Sornprom A, Chernrungroj G, Soussi T: Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking. Lung Cancer, 39: 297-301, 2003.
9. Angelopoulou K, Rosen B, Stratis M, Solomou M, Diamandis E: Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. Cancer, 77: 2146-2152, 1996.
10. Gottschlich S, Hoffman M, Maass J, Goeroegh T, Buhmann V, Hoffman-Fazel A, Rudert H, Maune S: p53 autoantibodies as tumor marker in head and neck squamous cell cancer. Anticancer Res, 23: 913-916, 2003.
11. Lavielle J, Righini C, Reyt E: Implications of p53 alterations and anti-p53 antibody response in head and neck squamous cell carcinomas. Oral Oncol, 34: 84-92, 1998.
12. Bourhis J, Lubin R, Roche B: Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst, 88: 1228-1233, 1996.
13. Werner JA, Gottschlich S, Folz BJ, Goeroegh T, Lippert BM, Maass JD, Rudert H: p53 serum antibodies as prognostic indicator in head and neck cancer. Cancer Immunol Immunother, 44: 112-116, 1997.
14. Maass J, Gottschlich S, Goeroegh T, Lippert BM, Werner JA: Head and neck cancer and p53 immunogenicity. Anticancer Res, 17: 2873-2874, 1997.
15. Angelopoulou K, Diamandis E: Detection of the TP53 tumor suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer. Eur J Cancer, 33: 115-121, 1997.
16. Rawal RM, Patel PS, Vyas RK, Sainger RN, Shah MH, Peshavariya HM, Patel DD, Bhatavdekar JM: Role of pretherapeutic biomarkers in predicting postoperative radiotherapy response in patients with advanced squamous cell carcinoma. Int J Radiation Biol, 77: 1141-1146, 2001.
17. Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Miyazawa Y, Shiratori T, Uno T, Ochiai T: Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery, 133: 24-31, 2003.
18. Regele S, Vogl F, Kohler T, Kreienberg R, Runnebaum I: p53 autoantibodies can be indicative of the development of breast cancer relapse. Anticancer Res, 23: 761-764, 2003.
19. Zalcman G, Schlichtholz B, Tredaniel J, Urban T, Lubin R, Dubois I, Milleron B, Hirsch A, Soussi T: Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to therapy. Clin Cancer Res, 4: 1359-1366, 1998.
20. Suzuki H, Akakura K, Igarashi T, Ueda T, Ito H, Watanabe M, Nomura F, Ochiai T, Shimada H: Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters. J Urol, 171: 182-186, 2004.
21. Shah JP (Ed): Cancer of the Head & Neck, pp 1-18. In: American Cancer Society Atlas of Clinical Oncology Series, BC Decker Inc, London, 2001.